Close

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Boehringer Ingelheim Integrates Owkin K Pro AI to Accelerate Drug Discovery

Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.
- Advertisement -

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and CEO at the Bernstein 32nd Annual Strategic Decisions Conference on Thursday, June 2, 2016 at 2:00 p.m. Eastern Daylight Time.

To listen to the webcast, visit our web site at www.pfizer.com and click on the “Bernstein 32nd Annual Strategic Decisions Conference” link in the For Investors section located on the lower right-hand corner of that page.

Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning today.

Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com.

Contact:

Joan Campion,
212-733-2798

Investor:

Bryan Dunn, 212-733-8917

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Boehringer Ingelheim Integrates Owkin K Pro AI to Accelerate Drug Discovery

Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.

EMA Initiates Data Sharing Pilot for New Approach Methodologies

The European Medicines Agency has launched a voluntary framework for sharing data from non-animal testing methods to build regulatory confidence and refine drug development.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »